Benzinga · Nov 9, 2026
Barclays Maintains Underweight on Baxter International, Raises Price Target to $23
Barclays analyst Christopher Pasquale maintains Baxter International (NYSE:BAX) with a Underweight and raises the price target from $20 to $23.

NYSE · BAX
Healthcare · Medical - Instruments & Supplies
$25.39
Down-$0.77 (-2.94%)
Updated Nov 20, 2026, 2:01 AM
SID Score
6.3/10
Composite research score
Smart Money
47/100
Neutral
Price performance · BAX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 19, 2026
BAX closed at $25.39 after 21 trading sessions, down 1.01% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 19, 2026 | $26.10 | $26.16 | $25.13 | $25.39 | 4.67M |
| Nov 18, 2026 | $25.56 | $26.46 | $25.52 | $26.16 | 4.01M |
| Nov 17, 2026 | $25.41 | $25.94 | $25.12 | $25.76 | 4.17M |
| Nov 16, 2026 | $25.79 | $26.13 | $25.505 | $25.54 | 6.16M |
| Nov 13, 2026 | $25.90 | $25.90 | $25.43 | $25.81 | 4.49M |
| Nov 12, 2026 | $26.595 | $26.66 | $25.645 | $25.74 | 4.67M |
| Nov 11, 2026 | $26.11 | $26.50 | $25.98 | $26.34 | 3.83M |
| Nov 10, 2026 | $26.18 | $26.49 | $25.57 | $26.42 | 3.83M |
| Nov 9, 2026 | $26.17 | $26.706 | $25.87 | $26.41 | 4.54M |
| Nov 6, 2026 | $24.99 | $25.825 | $24.7615 | $25.79 | 6.2M |
| Nov 5, 2026 | $26.82 | $26.97 | $25.09 | $25.65 | 10.1M |
| Nov 4, 2026 | $26.24 | $27.085 | $25.87 | $26.50 | 10.49M |
| Nov 3, 2026 | $24.04 | $25.57 | $23.90 | $25.49 | 9.4M |
| Nov 2, 2026 | $23.34 | $24.25 | $23.265 | $24.22 | 10.16M |
| Oct 30, 2026 | $23.59 | $23.59 | $22.495 | $23.00 | 11.82M |
| Oct 29, 2026 | $26.00 | $26.10 | $23.37 | $23.50 | 15.67M |
| Oct 28, 2026 | $25.11 | $26.025 | $24.93 | $25.46 | 12.43M |
| Oct 27, 2026 | $25.20 | $25.25 | $24.81 | $24.92 | 5.49M |
| Oct 26, 2026 | $25.62 | $25.62 | $25.06 | $25.29 | 4.04M |
| Oct 23, 2026 | $25.71 | $25.71 | $25.20 | $25.30 | 4.94M |
| Oct 22, 2026 | $24.73 | $25.705 | $24.68 | $25.65 | 5.21M |
The latest Smart Investors Daily articles mentioning BAX.
Company
Market Activity
Research & News
BAX research
Company profile and research snapshot.
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 9, 2026 | Barclays | Underweight | — |
| Oct 30, 2026 | JP Morgan | Neutral | — |
| Oct 30, 2026 | Wells Fargo | Equal-Weight | — |
| Oct 7, 2026 | Barclays | Underweight | — |
| Oct 5, 2026 | Citigroup | Neutral | — |
No generated briefing is available yet.
Benzinga · Nov 9, 2026
Barclays analyst Christopher Pasquale maintains Baxter International (NYSE:BAX) with a Underweight and raises the price target from $20 to $23.
Yahoo · Nov 6, 2026
Baxter International reported third quarter 2026 sales of US$2,976 million and net income of US$294 million, and raised its full year sales growth guidance from 4% to 5% from continuing operations. The return to profit over both the quarter and nine month period suggests Baxter International cost actions and portfolio work are starting to show through in reported earnings from continuing operations. This article examines how Baxter International's investment narrative intersects with its...
Yahoo · Nov 4, 2026
Baxter International has outperformed the broader market despite declining earnings, while higher guidance and debt reduction support optimism amid neutral analyst sentiment.
Yahoo · Nov 3, 2026
For questions about this article or underlying research, email [email protected].
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning BAX.